Hi Reader
Two immune-treatment stories broke in the same week, and I think they're worth sitting with together.
The first: a new oral tablet (a "BTK inhibitor" called remibrutinib) showed strong early results against relapsing MS — better than an existing oral drug on relapse rate and MRI-visible inflammation, with no red flags so far.
The second: an intensive cell-based therapy called CAR-T — where a patient's own immune cells are collected, re-engineered, and reinfused to wipe out the B cells driving disease — was paused across multiple trials after several patients died from severe immune reactions. This wasn't limited to one company or one condition; it touched lupus, rheumatoid arthritis, MS and more.
Same target, opposite ends of the spectrum
Both approaches are aimed at B cells, which really do play a central role in MS and several autoimmune conditions. But one is a daily tablet nudging a single signalling pathway. The other is a wholesale, engineered depletion of an entire immune cell population — borrowed from cancer treatment, where the risk-benefit calculation looks very different than it does in chronic autoimmune disease.
Why I'm not calling either one a verdict yet
The tablet's results are topline only — the full dataset isn't due until October, and until then we don't have the complete picture on relapse rates, side effects, or long-term safety. And the CAR-T pause is a serious signal, not proof that the whole approach has failed. Both deserve more time before anyone declares a winner.
What this means for how I think about "immune support"
You'll often hear phrases like "immune reset" or "switching off autoimmunity" as if there's one dial to turn. There isn't. Immune regulation and immune suppression are not the same thing, and there's a huge range of intervention between them — each with a different balance of disease control, infection risk, and loss of the protective immunity your body actually needs.
The takeaway
A strong headline isn't the same as complete data. A trial pause isn't the same as a failed category. And "immune modulation" covers an enormous range of very different interventions — knowing where something sits on that spectrum is what actually matters.
If you want help thinking through how immune-related treatment decisions fit into your broader health picture, hit reply or book a functional assessment — I'd love to help you get underneath it.
In Goode Health
Nicole